




RealRate

PHARMACEUTICAL 2019

Sonnet BioTherapeutics Holdings Inc. Rank 239 of 363





RealRate

PHARMACEUTICAL 2019

Sonnet BioTherapeutics Holdings Inc. Rank 239 of 363



The relative strengths and weaknesses of Sonnet BioTherapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet BioTherapeutics Holdings Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 119% points. The greatest weakness of Sonnet BioTherapeutics Holdings Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 143% points.

The company's Economic Capital Ratio, given in the ranking table, is 29%, being 7.4% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	1,675
Cost of Goods Sold	0
Intangible Assets	16,404
Liabilities, Current	14,312
Liabilities, Non-Current	3,000
Other Assets	1,247
Other Compr. Net Income	1,078
Other Expenses	40,689
Other Liabilities	4,223
Other Net Income	-2,545
Other Revenues	40,614
Property and Equipment	10,468
Research and Development	0
Selling, General and Administrative Expense	4,579

Output Variable	Value in 1000 USD
Assets	29,793
Liabilities	21,536
Expenses	45,268
Revenues	40,614
Stockholders Equity	8,258
Net Income	-7,199
Comprehensive Net Income	-6,660
Economic Capital Ratio	29%